Sciwind Biosciences

Focus: Sciwind Biosciences is a China-based biotech company specializing in oral peptide delivery technologies across metabolic, infectious, and respiratory diseases. The company is publicly listed and maintains an active pipeline spanning early to late-stage development.

Metabolic Diseases Infectious Diseases Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Sciwind Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Sciwind Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

XW001

Respiratory Syncytial Virus Infections

PHASE_1

Clinical Trials (1)

NCT05642403A Study of XW001 in Healthy Adult Subjects

Phase 1

Help build intelligence for Sciwind Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to emerging oral peptide delivery platform with 16 active clinical programs—a differentiated technology addressing major unmet needs in obesity and T2DM
Multiple Phase 3 programs (Ecnoglutide for T2DM, XW003 for OSA) represent near-term value inflection points and regulatory catalysts
Exposure to high-growth therapeutic areas (obesity, metabolic disease) where market demand is accelerating globally

Watch Out For

Currently zero active job openings despite public company status signals limited near-term hiring or organizational constraints
Minimal published data on financials, employee headcount, founding date, and cash position creates visibility gaps on company stability and growth trajectory
Geographically concentrated in China with limited transparency on regulatory pathway strategy for Western markets

Generated by Claude from Sciwind Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

XW003 injection

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT06335134A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Phase 1

Cohort A

Type 2 Diabetes Mellitus

PHASE_1

Clinical Trials (1)

NCT04389775To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants

Phase 1

XW003 injection

Obese Adolescents

PHASE_1

Clinical Trials (1)

NCT07143227A Study of XW003 Injection in Chinese Adolescents With Obesity

Phase 1

T2026

Obesity

PHASE_1

Clinical Trials (1)

NCT05184322XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Phase 1

XW014

Type 2 Diabetes Mellitus

PHASE_1

Clinical Trials (1)

NCT05579314XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

Phase 1

ecnoglutide tablets

Overweight and/or Obesity

PHASE_1_2

Clinical Trials (1)

NCT07243171A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Phase 1/2

XW001

RSV Infection

PHASE_1_2

Clinical Trials (1)

NCT05779995A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

Phase 1/2

XW003 injection

Obesity

PHASE_2

Clinical Trials (1)

NCT07073417A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)